Promis Neurosciences doses first subject in Phase 1a trial of PMN310 for Alzheimer's

ProMIS Neurosciences Inc.

First-in-human Phase 1a study of PMN310, a monoclonal antibody selective for toxic Aβ oligomers, is underway.
Up to 5 cohorts of 8 healthy volunteers each receive a single ascending dose; 85-day study with optional Day 120 follow-up.
Initial safety and pharmacokinetic data expected in first half of 2024.
Company raised >$20M in Q3 2023 private placement to support development through clinical milestones.
CEO Gail Farfel highlights transition to clinical stage and potential differentiation from other AD treatments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.